Cogstate Ltd Announces Share Buy-Back Update

TipRanksApr 22 19:07 ET

Enrolment Completed in Actinogen's XanaCIDD Phase 2a Cognition & Depression Trial

Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD

PR NewswireApr 22 08:30 ET

Cogstate Ltd Continues Share Buy-Back Initiative

TipRanksApr 15 19:17 ET

Cogstate Ltd Continues Share Buy-Back Program

TipRanksApr 14 19:27 ET

Cogstate (ASX:CGS) Shareholders Have Earned a 42% CAGR Over the Last Five Years

Yahoo FinanceApr 14 18:33 ET

Cogstate Continues Aggressive Share Buy-Back

TipRanksApr 8 19:17 ET